Evidence map›Paper›PMID 38420911›Full record

Observational studyFuture oncology (London, England)2024

An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study).

Yu Abe, Shiro Kubonishi, Masaki Ri, Masaki Iino, Kazutaka Sunami, Tomoki Ito, Masafumi Fukaya, Toshiyuki Kitano, Sho Ikeda, Shuichi Ota and 9 more

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 18 institutions in 1 country.

Yu AbeDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, 1508935, Japan.
Shiro KubonishiDepartment of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital, Himeji, Hyogo, 6708540, Japan.
Masaki RiDepartment of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Aichi, 4678602, Japan.
Masaki IinoDepartment of Medical Oncology, Yamanashi Prefectural Central Hospital, Kofu, Yamanashi, 4008506, Japan.ORCID 0000-0002-3471-0890
Kazutaka SunamiDepartment of Hematology, National Hospital Organization Okayama Medical Center, Okayama, 7011192, Japan.
Tomoki ItoDivision of Hematology, First Department of Internal Medicine, Kansai Medical University Medical Center, Moriguchi, Osaka, 5708507, Japan.
Masafumi FukayaDivision of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, Shizuoka, 4118777, Japan.
Toshiyuki KitanoDepartment of Hematology, Medical Research Institute Kitano Hospital, Osaka, 5308480, Japan.
Sho IkedaDepartment of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, 0108543, Japan.ORCID 0000-0002-3780-2993
Shuichi OtaDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Hokkaido, 0030006, Japan.
Taiga KuroiDepartment of Hematology, Chugoku Central Hospital, Fukuyama, Hiroshima, 7200001, Japan.
Noriyoshi IriyamaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, 1738610, Japan.
Tatsuro JoDepartment of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, 8528511, Japan.
Masaaki AdachiDepartment of Hematology, JCHO Sapporo Hokushin Hospital, Sapporo, Hokkaido, 0048618, Japan.
Daigo AkahaneDepartment of Hematology, Tokyo Medical University Hospital, Tokyo, 1600023, Japan.
Tatsuyuki KaiDivision of Hematology, Kita-Fukushima Medical Center, Fukushima, 9600502, Japan.
Yoichi KoharaDepartment of Hematology, Showa Inan General Hospital, Nagano, 3994117, Japan.
Norimitsu KadowakiDepartment of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, 7610793, Japan.
Teruaki KatayamaOncology Medical Affairs, Ono Pharmaceutical Co., Ltd, Osaka, 5418564, Japan.ORCID 0009-0003-9644-9397
Akita University · JPChugoku Central Hospital · JPHimeji Red Cross Hospital · JPHokushin General Hospital · JPJapanese Red Cross Medical Center · JPJapanese Red Cross Society, Japan · JPKagawa University · JPKansai Medical University · JPKitano Hospital · JPNagoya City University · JPNational Hospital Organization · JPNihon University · JPOno Pharmaceutical (Japan) · JPSapporo Hokuyu Hospital · JPShizuoka Cancer Center · JPShowa Inan General Hospital · JPTokyo Medical University Hospital · JPYamanashi Prefectural Central Hospital · JP

Funding

Ono Pharmaceutical
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsDexamethasoneMultiple MyelomaOligopeptidesAdultAgedAged, 80 and overDrug Administration ScheduleFemaleHumansJapanMaleMiddle AgedNeoplasm Recurrence, LocalProgression-Free SurvivalTreatment OutcomecarfilzomibDexamethasoneOligopeptidesARROW studycarfilzomibJapanesereal-worldrelapsed or refractory multiple myeloma

Identifiers

PMID38420911
PMCPMC11318723
OpenAlexW4392294402

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.